Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kainic acid is a naturally occurring, non-proteinogenic L-alpha-amino acid derived from the red alga Digenea simplex. It acts as a potent excitatory amino acid agonist, primarily targeting ionotropic glutamate receptors—specifically as a selective agonist at kainate receptors and as a partial agonist at AMPA receptors. By activating these glutamate receptor subtypes, kainic acid induces strong excitatory postsynaptic potentials (EPSPs) in neurons. In research settings, it is widely used to model epilepsy and study neurodegeneration due to its ability to induce seizures and excitotoxic neuronal death when administered in high concentrations. Kainic acid has also been used experimentally as an antinematodal agent[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kainic acid.